Business context and reporting period
Alpha Teknova, Inc. supplies research-use and GMP-grade reagents used in biopharmaceutical development, vaccines, diagnostics, and life-sciences research. This unaudited Form 10-Q covers the quarter and six months ended June 30, 2022. Unless noted otherwise, financial figures below are in millions of dollars.
Key financial metrics
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $11.7 | $8.3 | $22.8 | $17.4 |
| Gross profit | $5.2 | $3.4 | $10.6 | $8.4 |
| Gross margin | 44.9% | 40.3% | 46.4% | 48.2% |
| Operating loss | $(6.6) | $(2.5) | $(12.5) | $(3.4) |
| Net loss | $(6.2) | $(2.3) | $(11.7) | $(2.9) |
| Net loss per share, basic and diluted | $(0.22) | $(0.52) | $(0.42) | $(0.73) |
- Six-month operating cash use was $11.0 million; investing cash use was $16.8 million, primarily for property and equipment; financing provided $5.1 million. Cash and cash equivalents fell $22.8 million to $64.7 million at June 30.
- At June 30, total assets were $182.2 million, total liabilities $48.7 million, and stockholders’ equity $133.5 million. Current assets were $80.3 million versus current liabilities of $11.9 million.
- Long-term debt, net, was $16.8 million. The amended credit facility provides up to $57.1 million in commitments, including a $52.1 million term loan and a $5.0 million revolver; further term-loan draws are staged and some are conditional.
- Property, plant and equipment rose to $47.3 million from $29.8 million at year-end 2021. Construction in progress was $35.6 million.
Material changes versus the prior comparable period
- Revenue increased 40.6% in Q2 and 31.3% for the first half. Clinical Solutions grew 84.7% in Q2 and 153.6% for the first half; Lab Essentials grew 30.0% and 16.0%, respectively.
- Sample Transport revenue fell to negligible levels as demand for COVID-19 testing products declined; the company said it ceased production and marketing of sample transport medium in 2021.
- Q2 gross margin improved year over year, primarily because the comparable 2021 quarter included a $0.7 million Sample Transport inventory reserve. First-half margin declined year over year, reflecting higher labor costs, partly offset by that prior-year reserve.
- Operating expenses rose 101.9% in Q2 and 96.6% for the first half. Management attributed increases to hiring, product and process development, commercial expansion, professional fees, stock-based compensation, and public-company infrastructure.
- Cash use increased substantially versus first-half 2021, when IPO proceeds drove $112.1 million of financing cash flow. The company also adopted lease accounting in January 2022, recording lease assets and liabilities of approximately $20 million.
Outlook, risks, contingencies, and unusual items
- Management expects continued spending on personnel, automation, product development, sales and marketing, and capacity. A new Hollister manufacturing facility is expected to be a significant cash use over the next 6–12 months; the company expects capacity to expand substantially over the next two years.
- The company stated that cash and expected credit-facility availability should fund requirements for at least 24 months, but also said it was working with its lender to amend financial covenants to reflect a revised 2022 revenue outlook. The filing does not provide a clear numerical revised guidance figure or assurance that the lender will agree.
- A revenue covenant requires $42.5 million of trailing-12-month net revenue for the year ending December 31, 2022. Failure to comply could make debt immediately due and impair liquidity. Some future borrowing tranches also depend on Clinical Solutions revenue and liquidity thresholds.
- The facility is secured by substantially all company assets; term debt bears variable interest based on one-month LIBOR plus 6.45%, subject to a 1.00% floor, and has a May 2027 maturity. The filing cites LIBOR transition and interest-rate exposure.
- Major operating risks include scaling manufacturing without disrupting quality or delivery, reliance on a limited supplier base, customer order volatility and concentration, inflation and supply-chain constraints, and exposure to COVID-19 and broader economic uncertainty. One supplier accounted for 39% of Q2 inventory purchases; a distributor customer accounted for 14% of Q2 revenue.
- The company reported no material legal proceedings. Management said disclosure controls were effective and that a previously reported weakness related to complex, non-routine accounting transactions was remediated in Q1 2022.
Most important facts for investors to verify
- Whether the lender amended the revenue covenant, and whether the company meets the $42.5 million year-end threshold and other borrowing conditions.
- Whether revenue growth—particularly Clinical Solutions—can continue to support covenant compliance while operating expenses and losses remain elevated.
- Cash burn, capital spending, and the timing and cost of the Hollister facility build-out relative to available liquidity and staged debt funding.
- Whether supplier concentration, labor costs, and manufacturing expansion affect gross margins, product quality, or delivery times.
- How the company’s revised 2022 revenue outlook compares with actual results; the filing does not state a clear numerical revised outlook.